<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326063</url>
  </required_header>
  <id_info>
    <org_study_id>2017P001523</org_study_id>
    <nct_id>NCT03326063</nct_id>
  </id_info>
  <brief_title>Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban</brief_title>
  <official_title>Therapeutic Control of Aspirin-Exacerbated Respiratory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the study is to determine the efficacy of oral ifetroban, a novel
      antagonist of T prostanoid (TP) receptors, as a treatment for patients with
      aspirin-exacerbated respiratory disease (AERD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol involves a 4-week, double-blind, placebo-controlled parallel-design trial of
      oral ifetroban in patients with AERD. At the end of the 4-week treatment phase (ifetroban or
      placebo) each subject will undergo a graded oral aspirin desensitization procedure in order
      to initiate high-dose aspirin therapy, which is standard-of-care at our institution and is
      the only available therapy known to modify the course of AERD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 16, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Provocative Dose 2 (PD2) during aspirin challenge</measure>
    <time_frame>6 weeks from screening visit ( at visit 2)</time_frame>
    <description>The calculated dose of aspirin that induces an increase in the Total Nasal Symptom Score (TNSS) of 2 from the pre-aspirin challenge value, &quot;PD2&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchoconstriction during aspirin challenge</measure>
    <time_frame>6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Severity of bronchoconstriction during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspirin-induced Leukotriene E4 (LTE4) levels</measure>
    <time_frame>6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Increase of urinary and nasal levels of LTE4 during aspirin-induced reaction from Visit 2 pre-aspirin levels, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement of chronic disease - Forced Expiratory Volume 1 (FEV1)</measure>
    <time_frame>1 month (between Visit 1 and Visit 2)</time_frame>
    <description>Change from Visit 1 in baseline FEV1,compared between patients on placebo vs ifetroban.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement of chronic disease - Asthma Control Questionnaire (ACQ) score</measure>
    <time_frame>1 month (between Visit 1 and Visit 2)</time_frame>
    <description>Change from Visit 1 in baseline ACQ score, compared between patients on placebo vs ifetroban.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement of chronic disease - Sino-Nasal Outcome Test (SNOT-22) score</measure>
    <time_frame>1 month (between Visit 1 and Visit 2)</time_frame>
    <description>Change from Visit 1 in baseline SNOT-22 score at Visit 2, compared between patients on placebo vs ifetroban.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional exhaled Nitric Oxide (FeNO)</measure>
    <time_frame>1 month (between Visit 1 and Visit 2)</time_frame>
    <description>Change from Visit 1 in baseline FeNO levels at Visit 2, compared between patients on placebo vs ifetroban.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Urinary eicosanoid changes</measure>
    <time_frame>1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Change in levels of other urinary eicosanoids,from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Nasal eicosanoid changes</measure>
    <time_frame>1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Change in levels of nasal eicosanoids, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma/serum tryptase changes</measure>
    <time_frame>1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Change in levels of plasma/serum tryptase, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Nasal tryptase changes</measure>
    <time_frame>1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Change in levels of nasal tryptase, from Visit 1 to Visit 2 pre-aspirin challenge and Visit 2 pre-aspirin to during the aspirin-induced reaction at Visit 2, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelet activation - numbers of activated platelets</measure>
    <time_frame>1 month (between Visit 1 and Visit 2) and during aspirin challenge visit</time_frame>
    <description>Change in numbers of activated platelets in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelet activation - percentages of activated platelets</measure>
    <time_frame>1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Change in percentages of activated platelets in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelet activation - numbers of platelet-leukocyte aggregates</measure>
    <time_frame>1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Change in numbers of platelet-leukocyte aggregates in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelet activation - percentages of platelet-leukocyte aggregates</measure>
    <time_frame>1 month (between Visit 1 and Visit 2) and 6 weeks from screening visit ( at visit 2)</time_frame>
    <description>Change in percentages of platelet-leukocyte aggregates in the peripheral blood from Visit 1 to Visit 2 baseline (pre-aspirin administration) and during the aspirin-induced reaction at Visit 2 from Visit 2 baseline, compared between patients on placebo vs ifetroban, with the changes also analyzed with provocative aspirin dose as a covariate.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Nasal Polyps</condition>
  <condition>Asthma, Aspirin-Induced</condition>
  <condition>Aspirin-exacerbated Respiratory Disease</condition>
  <condition>Aspirin-Sensitive Asthma With Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Ifetroban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive placebo for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifetroban</intervention_name>
    <description>4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD</description>
    <arm_group_label>Ifetroban</arm_group_label>
    <other_name>ifetroban sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of AERD, defined as meeting the diagnostic triad with:

               -  History of physician-diagnosed asthma and

               -  History of physician-diagnosed nasal polyposis and

               -  History of pathognomonic reactions aspirin or other nonselective COX inhibitors.

          2. Stable asthma (post-bronchodilator FEV1 of â‰¥70%, no glucocorticoid burst for at least
             2 weeks prior to Visit 1, and no hospitalizations or ER visits for asthma for at least
             the prior 6 months)

          3. Age between 18 and 65 years

          4. No current smoking (not more than one instance of smoking in the last 3 months)

          5. Non-pregnant

        Exclusion Criteria:

          1. Hypersensitivity to montelukast

          2. Current use of zileuton

          3. History of bleeding diathesis or use of anticoagulant or antiplatelet drugs

          4. Current use of any NSAIDs aside from the aspirin provided during the study

          5. Current use of beta blockers

          6. Use of any biologics within the last 4 months prior to initiating the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Israel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanya M Laidlaw, MD</last_name>
    <phone>617-525-1034</phone>
    <email>tlaidlaw@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meghan Le</last_name>
    <phone>617-732-8201</phone>
    <email>mle8@bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asthma Research Center, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meghan Le</last_name>
      <phone>617-732-8201</phone>
      <email>mle8@bwh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Elliot Israel, MD</investigator_full_name>
    <investigator_title>Director of Asthma Research Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Asthma, Aspirin-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ifetroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

